Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine aloneSTEWART, V. Ann; MCGRATH, Shannon M; DEMOITIE, Marie-Ange et al.Infection and immunity. 2007, Vol 75, Num 5, pp 2283-2290, issn 0019-9567, 8 p.Article

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CSDUNACHIE, Susanna J; WALTHER, Michael; WATKINS, Katherine et al.Vaccine. 2006, Vol 24, Num 15, pp 2850-2859, issn 0264-410X, 10 p.Article

Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African AdultsDAY, Cheryl L; TAMERIS, Michele; BOLLAERTS, Anne et al.American journal of respiratory and critical care medicine. 2013, Vol 188, Num 4, pp 492-502, issn 1073-449X, 11 p.Article

Long-Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican ChildrenSACARLAL, Jahit; AIDE, Pedro; VEKEMANS, Johan et al.The Journal of infectious diseases. 2009, Vol 200, Num 3, pp 329-336, issn 0022-1899, 8 p.Article

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western KenyaSTOUTE, José A; GOMBE, Joash; STEWART, V. Ann et al.Vaccine. 2007, Vol 25, Num 1, pp 176-184, issn 0264-410X, 9 p.Article

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02AWALSH, Douglas S; GETTAYACAMIN, Montip; HOLLAND, Carolyn A et al.Vaccine. 2006, Vol 24, Num 19, pp 4167-4178, issn 0264-410X, 12 p.Article

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaKESTER, Kent E; MCKINNEY, Denise A; PALENSKY, Jolie et al.The Journal of infectious diseases. 2001, Vol 183, Num 4, pp 640-647, issn 0022-1899Article

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trialTHACHER, Eleonora G; CAVASSINI, Matthias; OFORI-ANYINAM, Opokua et al.AIDS (London). 2014, Vol 28, Num 12, pp 1769-1781, issn 0269-9370, 13 p.Article

Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development ImplicationsOUATTARA, Amed; TAKALA-HARRISON, Shannon; DIGGS, Carter L et al.The Journal of infectious diseases. 2013, Vol 207, Num 3, pp 511-519, issn 0022-1899, 9 p.Article

Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatisCOLER, Rhea N; BHATIA, Ajay; METTENS, Pascal et al.FEMS immunology and medical microbiology (Print). 2009, Vol 55, Num 2, pp 258-270, issn 0928-8244, 13 p.Article

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigenMETTENS, Pascal; DUBOIS, Patrice M; DEMOITIK, Marie-Ange et al.Vaccine. 2008, Vol 26, Num 8, pp 1072-1082, issn 0264-410X, 11 p.Article

Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. CommentaryALONSO, Pedro L; SACARLAL, Jahit; BASSAT, Quique et al.Lancet (British edition). 2004, Vol 364, Num 9443, pp 1380-1383, issn 0140-6736, 14 p.Article

Safety and immunogenicity of RTS, S+trap malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeysWALSH, Douglas S; PICHYANGKUL, Sathit; STEWART, Ann V et al.The American journal of tropical medicine and hygiene. 2004, Vol 70, Num 5, pp 499-509, issn 0002-9637, 11 p.Article

Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoitesMISHRA, Satish; RAI, Urvashi; SHIRATSUCHI, Takayuki et al.Vaccine. 2011, Vol 29, Num 43, pp 7335-7342, issn 0264-410X, 8 p.Article

Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of ProtectionKESTER, Kent E; CUMMINGS, James F; JUOMPAN, Laure et al.The Journal of infectious diseases. 2009, Vol 200, Num 3, pp 337-346, issn 0022-1899, 10 p.Article

Development of the RTS,S/AS malaria candidate vaccineVEKEMANS, Johan; LEACH, Amanda; COHEN, Joe et al.Vaccine. Supplement. 2009, Vol 27, Num 6, issn 1359-5938, G67-G71Conference Paper

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique : a double blind randomised controlled phase I/IIb trial. CommentaryEPSTEIN, Judith E; APONTE, John J; LEACH, Amanda et al.Lancet (British edition). 2007, Vol 370, Num 9598, issn 0140-6736, 1523-1524, 1543-1551 [11 p.]Article

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccineOCKENHOUSE, Christian F; ANGOV, Evelina; TORNIEPORTH, Nadia et al.Vaccine. 2006, Vol 24, Num 15, pp 3009-3017, issn 0264-410X, 9 p.Article

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria : progress at the Walter Reed army institute of researchGRAY HEPPNER, D; KESTER, Kent E; MORIS, Philippe et al.Vaccine. 2005, Vol 23, Num 17-18, pp 2243-2250, issn 0264-410X, 8 p.Conference Paper

HLA-A^*01-restricted cytotoxic t-lymphocyte epitope from the Plasmodium falciparum circumsporozoite proteinKUMAR, Anita; KUMAR, Sanjai; LE, Thong P et al.Infection and immunity. 2001, Vol 69, Num 4, pp 2766-2771, issn 0019-9567Article

A Field Trial to Assess a Blood-Stage Malaria VaccineTHERA, Mahamadou A; DOUMBO, Ogobara K; DIALLO, Dapa A et al.The New England journal of medicine. 2011, Vol 365, Num 11, pp 1004-1013, issn 0028-4793, 10 p.Article

Evaluation of the Safety and Immunogenicity of the RTS,S/AS01_E Malaria Candidate Vaccine When Integrated in the Expanded Program of ImmunizationAGNANDJI, Selidji T; ASANTE, Kwaku Poku; CHIKAWE, Maria et al.The Journal of infectious diseases. 2010, Vol 202, Num 7, pp 1076-1087, issn 0022-1899, 12 p.Article

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of ResearchKESTER, Kent E; CUMMINGS, James F; DOWLER, Megan G et al.Vaccine. 2008, Vol 26, Num 18, pp 2191-2202, issn 0264-410X, 12 p.Article

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeBEJON, Philip; LUSINGU, John; DEMOITIE, Marie-Ange et al.The New England journal of medicine. 2008, Vol 359, Num 24, pp 2521-2532, issn 0028-4793, 12 p.Article

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adultsKESTER, Kent E; MCKINNEY, Denise A; KRZYCH, Urszula et al.Vaccine. 2007, Vol 25, Num 29, pp 5359-5366, issn 0264-410X, 8 p.Article